Contact Us
Drug Search Results
More Filters [+]

Stamulumab

Alternative Names: stamulumab, myo-029, myo029, myo 029
Latest Update: 2023-06-03
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: GDF8 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Stamulumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Muscular Dystrophies, Limb-Girdle|Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophy, Duchenne|Muscular Dystrophy, Becker

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2004-000622-67

P2

Completed

Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophies, Limb-Girdle|Muscular Dystrophy, Becker

2007-01-31

3147K1-103

P1

Completed

Healthy Volunteers

None

3147K2-101

P2

Completed

Muscular Dystrophies, Limb-Girdle|Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophy, Duchenne|Muscular Dystrophy, Becker

None

Recent News Events

Date

Type

Title

06/03/2023

PubMed

 Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD): A Systematic Review.

05/18/2021

PubMed

 Current and Future Therapeutic Strategies for Limb Girdle Muscular Dystrophy Type R1: Clinical and Experimental Approaches.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions